How much revenue does Genocea Biosciences make?

Genocea Biosciences reported $1.64 million in revenue for fiscal year 2021, up 20.8% from $1.36 million in fiscal year 2020. In Q1 2022 revenue was $270,000.

What companies are similar to Genocea Biosciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Acura Pharmaceuticals, Inc. (ACUR), CEN Biotech, Inc. (CENBF), Praxsyn Corporation (PXYN), Imagenetix, Inc. (IAGX).

Genocea Biosciences, Inc. (GNCAQ) Stock

About Genocea Biosciences, Inc.

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in ...

At a glance

Genocea Biosciences reported revenue of $1.64 million for fiscal year 2021, up 20.8% from fiscal year 2020, and net income of -$33.20 million. In Q1 2022 (the quarter ended March 31, 2022) revenue was $270,000.

Figures from company filings; latest fiscal year ended December 31, 2021.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.